Renascience Inc. (TYO:4889)

Japan flag Japan · Delayed Price · Currency is JPY
2,915.00
+50.00 (1.75%)
Jul 22, 2025, 3:30 PM JST
721.13%
Market Cap36.42B
Revenue (ttm)132.00M
Net Income (ttm)113.00M
Shares Out12.71M
EPS (ttm)8.89
PE Ratio322.29
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,562,700
Average Volume2,410,220
Open2,815.00
Previous Close2,865.00
Day's Range2,808.00 - 3,055.00
52-Week Range263.00 - 3,055.00
Beta2.43
RSI69.38
Earnings DateAug 13, 2025

About Renascience

Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatm... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 3
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4889
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.